Gradient logo

Valentin Angelkov

CEO

Gradient

Gradient is involved in drug discovery utilizing proprietary quantum bio-chemistry platform. Gradient’s current discovery pipeline is centered around compounds with well-known safety profile (i.e. approved drugs and/or compounds that have been in clinical trials) that are active against novel, unrelated therapeutic targets associated with various cancers, neurodegeneration conditions and some rare and neglected diseases. Gradient initially validated its platform through the discovery of repurposed compounds found to be active against two tropical diseases – liver-stage malaria and African sleeping sickness.